be used to revive a person from death, although the first actual case was reported in 1774 when a 3-year-old trauma victim was revived with electric shocks to her chest delivered from an early capacitor called a Leyden jar. 1 More than 200 years later, the concept of terminating life-threatening arrhythmias with electric therapy has evolved greatly owing in part to the seminal work of Mirowski et al 2 and the development of the implantable cardioverter-defibrillator (ICD). 2 Although few would dispute the efficacy with which these devices recognize and terminate life-threatening ventricular arrhythmias, questions persist. In this issue of Circulation, Packer and colleagues 3 provide an important substudy of the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) and in doing so allow further insight into the both the marvels and limitations of ICD therapy.
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SCD-HeFT stands as the largest of the groundbreaking clinical studies that have firmly established the place of ICDs in the armamentarium of heart failure treatment. The trial randomized 2521 subjects with an ejection fraction Յ35% caused by either ischemic or nonischemic cardiomyopathy and New York Heart Association (NYHA) class II or III heart failure to receive conventional therapy alone, conventional therapy plus amiodarone, or conventional therapy with a shock-only single-chamber ICD. The study demonstrated a 23% reduction in all-cause mortality in patients randomized to receive an ICD with no benefit from amiodarone compared with conventional therapy. 4 What was not provided in the initial report is how the ICD reduced mortality, but Packer and colleagues have now supplied this missing piece. As anticipated, the reduction in mortality was driven exclusively by the 60% decrease in presumed ventricular tachyarrhythmia mortality compared with placebo because the device had no significant impact on death resulting from heart failure or noncardiac causes. 3 These results are consistent with the other clinical trials that published mode of death, with the Multicenter Automatic Defibrillator Implantation Trial (MADIT-II) and the Defibrillators in Nonischemic Cardiomyopathy Treatment Evaluation (DEFINITE) trial reporting a 67% and 80% decrease in arrhythmic death, respectively. 5, 6 While providing further support for the use of ICDs in patients with symptomatic left ventricular dysfunction, the study also raises important questions as to who actually benefits from device implantation. Although the study enrolled patients with NYHA class II and III heart failure, only those with class II heart failure derived a survival benefit from device placement. Even though one could have anticipated that neutral effects observed in class III patients were the result of a reduction in arrhythmic death offset by a higher risk of heart failure death, this did not appear to be the case. In fact, ICD use was not associated with a reduction in sudden death risk in class III patients, at least to any extent measurable from the available sample size. These findings stand in contrast to DEFINITE and MADIT-II in which patients with worse NYHA class derived equal or greater benefits from ICD therapy. Although differences in study populations may be the cause of these disparate findings, several other factors may play a role. As the authors suggest, there may be a subpopulation of class III patients with a markedly elevated risk of nonarrhythmic death that drives the results. In fact, SCD-HeFT participants deemed to be at highest risk of death resulting from heart failure as defined by the Seattle Heart Failure Model would actually be expected to have an increase in mortality after ICD placement because of the minimal contribution of sudden death caused by arrhythmia in such patients. 7 Additionally, the classification systems themselves may limit the interpretation of these results. Clinically defined sudden death may not always be arrhythmic in origin because other catastrophic entities may present in a similar manner. Furthermore, some arrhythmic events may serve as harbingers of impending pump failure, thus rendering the device ineffective at prolonging survival despite effectively terminating an episode of ventricular tachyarrhythmia. Analyses based on NYHA class are also limited, especially when such labels are assigned by hundreds of individual enrolling investigators, as was done in SCD-HeFT. Additionally, in a study with a median follow-up of nearly 4 years, patients may transition between heart failure classes several times. Thus, analyzing a time-dependent covariate only at the time of study enrollment can be misleading. Moreover, despite its widespread use, the NYHA classification is prone to considerable interobserver variation. 8 In other words, one physician's class II can be another physician's class III and visa versa.
Given these factors, withholding ICD therapy from patients with class III heart failure would appear misguided. SCD-HeFT enrolled a large number of class III patients; the primary end point was met; and any subgroup analyses should be viewed as hypothesis-generating exercises only. Current guidelines are consistent with this viewpoint as reflected by the class I indication given to ICD implantation in "SCD-HeFT-like" patients. When one attempts to apply a clinical trial to one's own practice, the more important question is not whether a particular subgroup benefited or not but whether the composition of the study cohort is similar to one's specific patient. In this regard, all ICD trials frequently fall short. Among the underrepresented are the elderly and patients with advanced chronic kidney disease, 2 of the fastest growing segments of the US population that make up 20% of current implantations. Further studies are sorely needed to define the utility of ICDs in these and other cohorts poorly represented in clinical trials.
SCD-HeFT may mark the last part of the first wave of major ICD trials for the primary prevention of sudden death, but important gaps in our knowledge remain. Risk stratification of patients already meeting implant criteria, if possible, will be an important step forward in delivering this remarkable technology in the most cost-beneficial manner possible. Many would acknowledge that ejection fraction alone is an imperfect measure for evaluating risk and recognize that additional variables can be used to identify patients with low ejection fraction who are unlikely to benefit from ICD placement because of either low risk of arrhythmic events or high risk of death from competing comorbidities. 9 Understandably, because guidelines for ICD placement are based primarily on ejection fraction, few are prepared to incorporate such risk stratification strategies into clinical practice. Work by Myerburg and colleagues 10 and others 11 also reminds us that the greatest absolute number of sudden deaths occur in patients with milder forms of heart disease, and the hypothesis that ICD therapy can reduce sudden cardiac death in these patients is being tested in clinical trials. Because these patients would be expected to have lower competing risk of death from other causes such as pump failure, finding those at sufficiently elevated risk of arrhythmic death to warrant device placement remains another great challenge.
Sudden cardiac arrest resulting from ventricular tachyarrhythmias remains a major public health concern. The degree to which ICDs terminate potentially life-threatening arrhythmias and extend life, as evidenced by SCD-HeFT, should at the very least result in the widespread adoption of this technology for the primary prevention of arrhythmic death in many, if not most, heart failure patients. Although the risk of sudden cardiac death exists along a continuum, great care must be taken as we look toward extending this therapy to a wider array of cardiac diseases. The costs, complications, and potential impact on quality of life of ICD therapy forces us to ask not only who may benefit but also who may benefit the most.
